MedTrace Logo

EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

NCT05570149 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-05-01

No results posted yet for this study

Summary

The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.

Conditions

  • Migraine Disorders

Interventions

DRUG

Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution

migraine prophylaxis

Sponsors & Collaborators

  • IRCCS San Raffaele Roma

    lead OTHER

Principal Investigators

  • Piero Barbanti, MD, PhD · IRCCS San Raffaele Roma

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05570149 on ClinicalTrials.gov